Evidence map›Paper›PMID 39280517›Full record

ArticleCureus2024

Assessing the Awareness of Psychotropic Medications Among the Saudi Population: Benefits, Risks, and Prevalence.

Anas Alhur, Afrah A Alhur, Enas Alrkad, Muteb H Alshammari, Noura Harbi, Leen Alshareef, Mohammad Alfaqeh, Taif Alayyafi, Abdulrahman Mohammed, Asayel Alamri and 5 more

Abstract read
In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anas AlhurHealth Informatics, University of Hail College of Public Health and Health Informatics, Hail, SAU.
Afrah A AlhurUOH, University of Hail, Hail, SAU.
Enas AlrkadPharmacy, Salamat Medical Complex, Hail, SAU.
Muteb H AlshammariHealth Informatics, University of Hail, Hail, SAU.
Noura HarbiPharmacy, Najran Armed Forces Hospital, Najran, SAU.
Leen AlshareefPharmacology, King Khalid University, Abha, SAU.
Mohammad AlfaqehPharmacology, Jazan University, Jazan, SAU.
Taif AlayyafiPharmacology, Umm al-Qura University, Makkah, SAU.
Abdulrahman MohammedCommunity Pharmacy, Ministry of Health, KSA, SAU.
Asayel AlamriPharmacology, Umm al-Qura University, Makkah, SAU.
Haya AlrowaebeiPatient Care, Maternity and Children's Hospital, KSA, SAU.
Lamah AllehaibiPharmacology, Umm Al-Qura University, Makkah, SAU.
Abdulaziz AlosaimiPharmacology, Taif University, Taif, SAU.
Rehab AlbishiNursing, King Abdullah Hospital, Hail, SAU.
Maha AlThawwabPharmacy, AlNahdi Medical Company, KSA, SAU.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Mental health treatment, particularly through psychotropic medications, is becoming increasingly prominent worldwide. In Saudi Arabia, the acceptance and understanding of these treatments are shaped by unique cultural and social factors. Despite some awareness, there remains a need for deeper insights into the public's perceptions and knowledge of psychotropic medications. This study aims to examine the awareness levels of psychotropic medications among the Saudi population, their perceived benefits and risks, the prevalence of their use, and any demographic differences in these perceptions. Methods Employing a quantitative, cross-sectional design, this study collected data via an online questionnaire from Saudi residents aged 18 and above. The questionnaire, validated by experts, covered demographic details, awareness and knowledge of psychotropic medications, and personal or vicarious experiences with these medications. Data analysis was performed using SPSS (IBM Corp., Armonk, NY, USA), applying descriptive and inferential statistics to provide a comprehensive view of the current landscape. The study was conducted over four weeks, from May 1, 2024, to May 31, 2024. Results The study indicated a demographic skew towards younger individuals, with a significant predominance of female respondents (70.86%, n=1024). A notable 63.52% (n=922) of participants reported being aware of psychotropic medications. Regarding knowledge, 37.83% (n=549) of respondents were somewhat knowledgeable about the benefits, while 37.57% (n=545) were somewhat knowledgeable about the risks. The prevalence of use was reported by 41.92% (n=608) of respondents, mainly through acquaintances rather than personal use. Younger, predominantly female, and well-educated individuals demonstrated higher levels of awareness and acceptance of psychotropic medications. Significant variations in perceptions were observed based on age, gender, and educational level. Respondents aged 18-24 years (52.52%, n=762) were significantly more likely to be aware of psychotropic medications (p < 0.01), and female respondents showed a higher acceptance rate (p < 0.05). Educational level also played a crucial role, with college-educated individuals (63.38%, n=919) displaying greater acceptance and awareness compared to those with only a high school education (28.24%, n=409) (p < 0.01). The general opinion on the effectiveness and adequacy of public information about psychotropic medications was mixed, with 52.93% (n=768) acknowledging their benefits while 31.92% (n=463) expressed concerns about side effects, indicating a need for improved public education. Conclusion The study emphasizes the importance of enhancing public education and awareness initiatives to improve knowledge and acceptance of psychotropic medications in Saudi Arabia. This could lead to better mental health outcomes and broader acceptance of these treatment options.

Indexed as

medication safetymental health awarenesspsychological medicationspublic healthsaudi arabia

Identifiers

PMID39280517
PMCPMC11393380

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.